On December 7, 2022, Inozyme Pharma, Inc. and Henric Bjarke entered into an executive transition, separation and release of claims agreement providing for Mr. Bjarke's resignation as Senior Vice President and Chief Operating Officer of the Company. Mr. Bjarke's resignation is a result of his decision to relocate internationally for family and personal reasons. The effective date of Mr. Bjarke's resignation is December 31, 2022.

On December 7, 2022, the Company and Mr. Bjarke also entered into a consulting agreement, pursuant to which Mr. Bjarke has agreed to provide consulting and advisory services related to the Company's precommercial and commercial preparedness and business development activities from January 1, 2023 to June 30, 2023, unless earlier terminated. The Company has commenced a search for Mr. Bjarke's successor.